- 1 Spatial and Temporal Distribution of Visceral Leishmaniasis in Karamoja Region,
- 2 Uganda: Analysis of surveillance data, 2015–2022
- 3 Authors: Mercy Wendy Wanyana^{1*}, Richard Migisha¹, Patrick King¹, Benon Kwesiga¹,
- 4 Daniel Kadobera¹, Lilian Bulage¹, Alex Riolexus Ario¹
- 5 Institutional affiliations: ¹Uganda Public Health Fellowship Program, Uganda National
- 6 Institute of Public Health, Kampala, Uganda
- 7 ***Correspondence:** Email: <u>mwanyana@uniph.go.ug</u>, Tel: +256779207928
- 8
- 9

10 Abstract

- 11
- 12 **Background:** Uganda targets to control leishmaniasis and eliminate visceral
- leishmaniasis as a public health problem by 2030, with 85% of the cases detected, 95%
- treated, and visceral leishmaniasis eliminated (<1% case fatality rate [CFR]). However,
- 15 little is documented on the country's progress towards achieving these targets. We
- 16 examined the temporal trends and spatial distribution of leishmaniasis in the endemic
- 17 Karamoja Region of Uganda, 2015–2022.
- 18 **Methods:** We analysed aggregate secondary data on clinically diagnosed leishmaniasis
- 19 laboratory-confirmed cases, visceral leishmaniasis cases, hospital admissions, and
- 20 deaths from the District Health Information System 2. We used population-based
- calculations to determine the annual prevalence of leishmaniasis and quarterly
- 22 prevalence of visceral leishmaniasis per 1,000,000 persons, while the prevalence of
- leishmaniasis admissions and CFRs were calculated per 100 cases. We used the
- 24 Mann-Kendall test to assess the significance of the trend.
- **Results:** Overall, 4,008 cases of clinically diagnosed leishmaniasis were reported, and
- of these, 11% were laboratory-confirmed. The average annual prevalence of
- leishmaniasis was 4 per 1,000,000 population. From 2020 to 2022, there was an
- increasing trend in quarterly prevalence of visceral leishmaniasis (Kendall's score=36,
- p=0.016), averaging 3 cases per 1,000,000 population. Leishmaniasis admissions
- increased annually to 55 per 100 cases (Kendall's score=23, p=0.006). The average
- annual CFR was 5%, with no deaths reported in 2018, 2019, and 2021. Amudat District
- had the highest prevalence rates of leishmaniasis (477 per 1,000,000 population) and
- visceral leishmaniasis (139 per 100,000 population).
- **Conclusion:** The increasing trend of visceral leishmaniasis, and CFR >1% threaten the
- 35 goal of controlling leishmaniasis as a public health problem by 2030. Gaps in case
- detection may further prevent the achievement of targets. Strengthening existing
 interventions, such as vector control and rapid diagnostic kits for early detection and
- treatment, may be crucial to sustain progress toward elimination targets.
- 39
- 40 Keywords: Leishmaniasis, Visceral leishmaniasis, Disease control, Uganda
- 41

43 Background

44 Leishmaniasis is a vector-borne neglected tropical disease caused by a protozoan and transmitted by a female sand fly mainly of *Phlebotomus* species¹. Transmission occurs 45 when an infected female sand fly bites a human host and transmits the parasite to the 46 47 host during its blood meal². The disease clinically manifests in three forms: cutaneous, mucocutaneous and visceral³. Clinical presentation usually depends on the virulence of 48 49 the parasite, the individual's immunity, and the site of the lesion⁴. The cutaneous form is 50 the mildest form, typically presenting with painless nodules, macules, papules or ulcerative lesions on the skin in areas exposed to bites of the sand fly. It is commonly 51 linked to the *Leishamania major* and *Leishmania tropica species*². The mucosal form 52 53 typically presents with lesions on the mucus membranes and cartilage in the nose, mouth, upper respiratory tract, and pharynx⁵. Visceral leishmaniasis manifests as fever, 54 55 weight loss, splenomegaly, hepatomegaly, and reduced blood cell production, potentially causing anemia, bleeding, and susceptibility to other infections^{6,7} Visceral 56 Leishmaniasis, often associated with L. donovani in East Africa, is highly fatal with a 57 95% untreated case fatality rate and 10-20% with treatment^{8,9}. It carries outbreak 58 59 potential, with sequelae like relapse and post-kala-azar dermal leishmaniasis, contributing to interepidemic reservoirs and sustaining transmission. 60 61 As of 2019, approximately 4,580,000 cases of leishmaniasis were reported globally, 62 causing an estimated 657,000 new cases annually and resulting in 697,000 Disease 63 Adjusted Life Years (DALYs) lost¹⁰. African countries including Uganda contribute a 64 significant proportion of the burden, accounting for 34-57% ¹¹. Leishmaniasis 65 disproportionately impacts the poorest populations due to factors such as inadequate 66 housing, poor environmental sanitation, lack of control measures, and economically 67 driven migration to vector-prone areas, increasing their susceptibility to the disease ^{12,13}. 68 Children and immunocompromised individuals, including People Living with HIV 69 (PLWHIV), are more affected than adults and non-immunocompromised individuals^{14,15}. 70 71 Leishmaniasis places a catastrophic financial burden on affected households with a 72 median cost ranging from USD 165 to 1,500 per episode^{13,16}. To avert this burden, 73 current global efforts aim at controlling leishmaniasis and eliminate leishmaniasis by 74 75 2030 through the World Health Organization(WHO) Roadmap for neglected tropical diseases 2021–2030¹⁷. Specifically, this aims to ensure that 85% of all leishmaniasis 76 cases are detected, 95% treated, and visceral leishmaniasis eliminated (<1% case 77 78 fatality rate [CFR]); this includes Uganda where the disease is endemic especially in the Karamoja Region. Currently there is a paucity of data on the country's progress and 79 burden of leishmaniasis. This could be attributed to the limited analysis of surveillance 80 data despite it's being in the national integrated disease surveillance system.¹⁸ Analysis 81 of the surveillance data is key to detect remaining or re-emerging hotspots of 82 leishmaniasis transmission which supports timely adaptation of control and elimination 83 interventions¹⁹. Given the complexity of leishmaniasis management and diagnostics, 84 control efforts adopt an innovative and intensified disease management approach. 85 emphasizing individual care at health facilities²⁰. As such, understanding trends in 86 health facility leishmaniasis data is crucial for evidence-based decision-making. We 87

88 examined the temporal trends and spatial distribution of leishmaniasis in the endemic

89 Karamoja Region of Uganda, 2015–2022.

90 Methods

91 Study settings

92 We utilised leishmaniasis surveillance data generated from all health facilities in the

- 83 Karamoja region in the years 2015–2022. Leishmaniasis is endemic in the Karamoja
- region in Uganda. The semi-arid climate and termite hills in this region provide a
- 95 favourable environment for sand flies of *Phlebotomus* species which are the vector
- responsible for transmission of Visceral Leishmaniasis²¹. Within Uganda health facilities
- 97 leishmaniasis is diagnosed clinically and confirmed using a Giemsa-stain slides viewed
- 98 under a microscope.

99 Study design and data Source

We conducted a descriptive study using routinely collected leishmaniasis surveillance 100 data collected in District Health Information System 2 (DHIS-2) .The DHIS-2 collects 101 data on diseases of public health importance like leishmaniasis based on the Integrated 102 Disease Surveillance and response guidelines.²² It includes data on both clinically 103 diagnosed and laboratory confirmed leishmaniasis cases, admissions, primary visceral 104 leishmaniasis i.e. without history of visceral leishmaniasis treatment, relapse i.e. with 105 history of visceral leishmaniasis treatment, post-kala-azar dermal leishmaniasis, a 106 complication of visceral leishmaniasis and leishmaniasis HIV co-infection, and deaths. 107 Before 2020, all forms of leishmaniasis (cutaneous, visceral and mucosal) were 108 reported jointly in the monthly outpatient and in-patient registers. In 2020, an in-patient 109 tool that collects primary visceral leishmaniasis, relapse and leishmaniasis HIV co-110 infection was introduced. In this study, we utilized aggregate data of on leishmaniasis 111 from monthly outpatient reports (Health Management Information System forms [HMIS] 112 105) 2015–2022, inpatient monthly reports (HMIS 108) 2015–2022, and (HMIS 127b) 113 2020-2022. 114

115 Study variables, data management, and analysis

116 We downloaded the data regarding clinically-diagnosed and laboratory-confirmed

117 leishmaniasis cases and admissions, primary visceral leishmaniasis, relapse visceral

- 118 leishmaniasis, post-kala-azar dermal leishmaniasis, and visceral leishmaniasis HIV co-
- infection, and death.in excel and imported in STATA version 16 software (StataCorp,
- 120 College Station, Texas, USA) for analysis. Using data on leishmaniasis and visceral
- leishmaniasis cases, we calculated the annual prevalence of leishmaniasis as
- 122 laboratory confirmed leishmaniasis cases divided by the population in the region. From
- 2020 to 2022, we assessed the proportions of primary, relapse, post-kala-azar dermal
- 124 leishmaniasis, and HIV co-infection among admitted Visceral Leishmaniasis cases.
- 125 Quarterly prevalence of Visceral Leishmaniasis was calculated as the ratio of primary
- and relapse cases to the population, obtained from Uganda Bureau of Statistics.
- 127 Leishmaniasis admissions and hospitalization prevalence were determined using

leishmaniasis cases as denominators. Case fatality rates were computed based on the

proportion of deceased leishmaniasis cases. Line graphs were used to show trends,

and Mann-Kendall test to assess the significance of trends. We used choropleth maps

131 created with QGIS software to illustrate the spatial distribution of leishmaniasis in the 132 region.

133 Ethical Considerations

134 Our study utilized routinely generated aggregated surveillance data with no personal

identifiers in health facility outpatient and in-patient monthly reports, obtained from the

136 DHIS-2. The Uganda Public Health Fellowship Program is part of the National Rapid

137 Response Team, and has been granted permission to access and analyse surveillance

data in the DHIS-2 and other data such as survey and field investigation data to inform

- decision making in the control and prevention of outbreaks and public health
- programming. Additionally, the Ministry of Health (MoH) has also granted the program
- 141 permission to disseminate the information through scientific publications. We stored the 142 abstracted data set in a password-protected computer and only shared it with the
- investigation team. In addition, the Office of the Associate Director for Science, U.S.

144 Centers for Disease Control and Prevention, determined that this study was not a

human subjects research with the primary intent of improving use of surveillance data to

146 guide public health planning and practice.

147 This activity was reviewed by CDC and was conducted consistent with applicable

148 federal law and CDC policy.§


\$See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44
 U.S.C. §3501 et seq.

151

152 **Results**

153 Trends in the prevalence of leishmaniasis, Karamoja Region, Uganda, 2015-2022

Reporting rates for the Karamoja region ranged from 96% to 100% during the review period (from 2015 to 2022). Overall, 4,008 clinically-diagnosed leishmaniasis cases were reported. Of these, 484 (11%) were confirmed. The average annual prevalence of leishmaniasis was 4 cases per 1,000,000 population in the Karamoja Region reported from 2015 to 2022. No trend in leishmaniasis prevalence was observed, Kendall's score=-13, p=0.173 (Figure 1).



160

Figure 1: Trends in annual leishmaniasis prevalence, Karamoja Region, Uganda, 2015–2022

163

Trends of the quarterly prevalence of visceral leishmaniasis, Karamoja Region, Uganda, 2020–2022

166 Over the review period, 602 visceral leishmaniasis cases were reported. Of these 540


167 (90%) were primary visceral leishmaniasis cases while 62 (10%) were relapse cases. Of

the total cases, 4 (1%) were visceral leishmaniasis HIV-coinfected and 5 (1%) were

post-kala-azar dermal leishmaniasis. The average quarterly prevalence of visceral
 leishmaniasis cases was 3 cases per million with the highest prevalence (5 cases per

leishmaniasis cases was 3 cases per million with the highest prevalence (5 cases per
 1,000,000 population) reported in the guarter 3 of 2022 (Figure 2). From 2020 to 2022,

- there was an increasing trend in the quarterly prevalence of visceral leishmaniasis,
- 173 Kendall's score=36, p=0.016.



174

Figure 2: Trends in quarterly prevalence of visceral leishmaniasis, Karamoja
 Region, Uganda, 2020–2022.

177 Trends of leishmaniasis admissions, Karamoja Region, Uganda, 2015–2022

178 From 2015 to 2022, the average annual prevalence of leishmaniasis admission in the


179 Karamoja region was 52 cases per 100 cases. The highest incidence of leishmaniasis

admissions were reported in the years 2020 (87 leishmaniasis admissions per 100

cases), 2021 (93 leishmaniasis admissions per 100 cases), and 2022 (92 leishmaniasis

admissions per 100 cases) (Figure 3). Overall there was an increasing trend of

leishmaniasis admissions, Kendall's score= 23, p=0.006.



184

Figure 3: Trends in hospital admissions due to leishmaniasis in Karamoja Region, Uganda, 2015–2022.


187

188 Leishmaniasis case fatality rate, Karamoja region, Uganda, 2015–2022

During the review period, the average annual CFR was 5% (Range: 0-11%), with no

deaths reported in 2018, 2019, and 2021. The highest case fatality rates was recorded in

- 191 2020. No trends were observed in the case fatality rate, Kendall's score= -2, p=0.947
- 192 (Figure 4).



194

Figure 4: Trends in leishmaniasis case fatality rate, Karamoja Region, Uganda, 2015–2022

197 Spatial distribution of Leishmaniasis, Karamoja Region, Uganda, 2015–2022

198 Within the Karamoja Region, Amudat District reported the highest average annual


prevalence of both leishmaniasis (477 per 1,000,000 population) and visceral


leishmaniasis (139 per 100,000 population). Abim, Kaabong, Karenga, and Nabilatuk

did not report both leishmaniasis and visceral leishmaniasis cases during the reporting
 period.

203

193





205

206 Figure 5: Spatial distribution of leishmaniasis and visceral leishmaniasis,

207 Karamoja Region, Uganda, 2015–2022

208

209 Discussion

In this analysis to examine the temporal trends and spatial distribution of leishmaniasis 210 in an endemic Karamoja Region of Uganda, 2015–2022, only 11% of the clinically-211 diagnosed leishmaniasis cases were laboratory confirmed. Over the review period, no 212 changes were observed in the annual prevalence of leishmaniasis. While most visceral 213 leishmaniasis cases were primary, we identified relapse, post-kala-azar dermal 214 leishmaniasis, and visceral leishmaniasis HIV coinfected cases between 2020 and 215 2022. A rising trend in guarterly prevalence of visceral leishmaniasis occurred from 216 guarter one (Q1) 2020 to guarter four (Q4) 2022, along with an increase in hospital 217 admissions due to leishmaniasis. The average annual CFR remained <1%, with no 218 deaths reported in 2018, 2019, and 2021. Amudat District had the highest leishmaniasis 219 220 prevalence. 221 We identified gaps in case detection, with only 11% of clinically-diagnosed cases 222

confirmed by laboratory investigations. Leishmaniasis shares clinical features with
 common regional illnesses like malaria, typhoid, and tuberculosis, emphasizing the
 importance of laboratory confirmation in case detection²³. In the East African region,

numerous factors may hinder laboratory confirmation for leishmaniasis including low

proportions of health facilities with microscopes and microscopy supplies and trained
 staff in leishmaniasis testing²⁴. Such existing gaps may hinder achievement of

leishmaniasis targets of 85% of all leishmaniasis cases detected.

230

In contrast to the global declining trends in leishmaniasis prevalence, no significant trends were observed in the Karamoja Region for leishmaniasis cases from 2015 to

2022^{25,26}. The Karamoja Region like the rest of East Africa faces unique challenges that 233 234 may prevent declines despite targets. The Karamoja Region like the rest of East Africa 235 faces unique challenges that may prevent declines despite targets, including poor atrisk population with limited access to healthcare and insecurity in endemic regions¹⁹. 236 237 Our findings further indicated an increase in the guarterly prevalence of visceral 238 leishmaniasis cases from 2020 to 2022. This trend is similar to global leishmaniasis surveillance data that indicated an increase in visceral leishmaniasis in the East African 239 Region during 2020¹¹. During this period, vital control programs supporting the region, 240 such as the Accelerating the Sustainable Control and Elimination of Neglected Tropical 241 Diseases, were terminated. This resulted in the scaling down of control efforts²⁷. The 242 increase in visceral leishmaniasis cases following termination of control programmes 243 may undo previous gains towards achievement of elimination targets. Furthermore, we 244 found Visceral Leishmaniasis relapse and post-kala-azar dermal leishmaniasis (PKDL) 245 cases. The presence of these cases contributes to the maintenance of infectious 246 reservoirs, posing a threat to the achievement of elimination targets²⁸. 247

Our findings revealed a considerable number of hospital admissions due to 248 leishmaniasis. This suggests a sustained burden of visceral leishmaniasis whose illness 249 and management often requires hospitalisation²⁹. Admissions due to leishmaniasis 250 impose a substantial economic burden on households, with a median expenditure of 251 450 US dollars per hospital stay due to leishmaniasis³⁰. We found that hospital 252 admissions linked to leishmaniasis increased. This might suggest gaps in treatment of 253 leishmaniasis resulting in leishmaniasis complications that may require in-patient 254 admissions. 255 The average annual CFR was still greater than the 1% target by 2030. This indicated 256

that Uganda is yet to achieve the control leishmaniasis and eliminate visceral
leishmaniasis as a public health elimination. The no trend observed in CFR and its
substantial variation in the CFR from 0 to 11% suggests a need for intensifying efforts to
ensure targets are met. Such efforts include improving prompt diagnosis of visceral
leishmaniasis using rapid diagnostic kits and increasing access to prompt effective
treatment.

In regards to the current distribution, Amudat had the highest prevalence of both
 leishmaniasis and visceral leishmaniasis. This pattern may be attributed to presence of
 a referral leishmaniasis treatment centre at Amudat Hospital³¹.

Our findings should be interpreted with considerations of the following limitations. Our use of facility-based data may lead to an underestimation of the true disease burden, capturing only individuals seeking healthcare. Previous studies have indicated that surveillance data may underreport the burden of leishmaniasis up to 8 fold for visceral leishmaniasis and 5 fold for cutaneous leishmaniasis⁹. Additionally, our reliance on aggregate data restricted further exploration of prevalence in population subcategories and specific clinical types of leishmaniasis.

273 Conclusion

274 The current burden of leishmaniasis coupled with gaps in case detection threatens the

achievement of control of leishmaniasis targets. While the increasing trends of visceral

- leishmaniasis and variation in case fatality rates question whether achieved visceral
- leishmaniasis targets will be met by 2030. Existing interventions should be intensified to
- including vector control, rapid diagnostic kits for early detection and prompt treatment
- should be intensified to sustain the achievement of elimination targets.
- 280

281 List of abbreviations

- 282 CFR: Case Fatality Rate
- 283 DHIS-2: District Health Information System 2
- 284 HMIS: Health Management Information System
- 285 NTD: Neglected Tropical Disease
- 286 PKDL: Post-kala-azar Dermal Leishmanisis
- 287
- 288
- 289
- 290
- 291
- 292
- 293

294 Acknowledgements

295 We would like to thank the Ministry of Health for providing access to DHIS2 data that

was used for this analysis. We appreciate the technical support provided by the Division

of Surveillance, Information and Knowledge Management and the Division of Vector

298 Control. Finally, we thank the US-CDC for supporting the activities of the Uganda Public

- Health Fellowship Program.
- 300

301 **References**

- Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R.
 Leishmaniasis: a review. F1000Research. 2017;6:750.
- Bates PA. Transmission of Leishmania metacyclic promastigotes by phlebotomine
 sand flies. Int J Parasitol. 2007 Aug;37(10):1097–106.
- Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet (London, England). 2018
 Sep;392(10151):951–70.
- Mokni M. [Cutaneous leishmaniasis]. Ann Dermatol Venereol. 2019
 Mar;146(3):232–46.
- Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol [Internet]. 2015 Dec 1;73(6):897–908. Available from: https://doi.org/10.1016/j.jaad.2014.08.051
- Bi K, Chen Y, Zhao S, Kuang Y, John Wu C-H. Current Visceral Leishmaniasis
 Research: A Research Review to Inspire Future Study. Biomed Res Int.
 2018;2018:9872095.
- van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012
 Jun;26(2):309–22.
- Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol [Internet]. 2007;5(11):873–82. Available from: https://doi.org/10.1038/nrmicro1748
- Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis
 worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.
- IHE (Institute for Health Metrics and Evaluation). Leishmaniasis- Level 3 Cause
 [Internet]. 2019 [cited 2023 Feb 1]. Available from:
 https://www.healthdata.org/results/gbd_summaries/2019/leishmaniasis-level-3 cause
- mondiale de la Santé O, Organization WH. Global leishmaniasis surveillance:
 2019–2020, a baseline for the 2030 roadmap–Surveillance mondiale de la
 leishmaniose: 2019-2020, une période de référence pour la feuille de route à

- l'horizon 2030. Wkly Epidemiol Rec Relev Épidémiologique Hebd.
- 333 2021;96(35):401–19.
- Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 2006
 Dec;22(12):552–7.
- 13. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. Am J
 Trop Med Hyg. 2016 Mar;94(3):489–93.
- Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and
 HIV coinfection: current perspectives. HIV AIDS (Auckl). 2018;10:193–201.
- Gupta AK, Singh A, Srivastava S, Shankar P, Singh S. Visceral Leishmaniasis in
 children: Diagnosis, treatment, and prevention. J Pediatr Infect Dis.
 2017;12(04):214–21.
- 16. Uranw S, Meheus F, Baltussen R, Rijal S, Boelaert M. The Household Costs of
 Visceral Leishmaniasis Care in South-eastern Nepal. PLoS Negl Trop Dis
 [Internet]. 2013 Feb 28;7(2):e2062. Available from:
 https://doi.org/10.1371/journal.pntd.0002062
- 17. Casulli A. New global targets for NTDs in the WHO roadmap 2021–2030. PLoS
 Negl Trop Dis [Internet]. 2021 May 13;15(5):e0009373. Available from: https://doi.org/10.1371/journal.pntd.0009373
- MoH (Minstry of Health Uganda). Sustainability Plan for Neglected Tropical
 Diseases Control Program [Internet]. Kampala, Uganda; 2020. Available from:
 http://library.health.go.ug/publications/neglected-tropical-diseases/sustainability plan-neglected-tropical-diseases-control
- Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis
 as a public health problem in east Africa: reflections on an enhanced control
 strategy and a call for action. Lancet Glob Heal. 2021 Dec;9(12):e1763–9.
- Engels D, Zhou X-N. Neglected tropical diseases: an effective global response to
 local poverty-related disease priorities. Infect Dis Poverty [Internet]. 2020;9(1):10.
 Available from: https://doi.org/10.1186/s40249-020-0630-9
- Jones CM, Welburn SC. Leishmaniasis Beyond East Africa. Front Vet Sci.
 2021;8:618766.
- MoH (Minstry of Health Uganda). National Technical Guidelines for Integrated
 Disease Surveillance and Response Third Edition [Internet]. 2021. Available from:
 https://www.afro.who.int/sites/default/files/2021-09/2_Uganda 3rd IDSR Tech
 Guideline_PrintVersion_10Sep2021.pdf
- Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of
 parasitological, immunological and molecular methods. J Parasit Dis Off organ
 Indian Soc Parasitol. 2020 Jun;44(2):253–72.
- de Souza DK, Picado A, Bessell PR, Liban A, Wachira D, Mwiti D, et al.
 Strengthening Visceral Leishmaniasis Diagnosis Capacity to Improve Access to

- 371 Care in Kenya: The Example of Marsabit County. Front Trop Dis [Internet].
- 372 2022;2. Available from:
- https://www.frontiersin.org/articles/10.3389/fitd.2021.809757
- Alatif H. Burden and Trends of Leishmaniasis over the last one Decade Across
 the Globe: Trend Analysis of WHO Regions. Integr J Med Sci [Internet]. 2020;8.
 Available from: https://mbmj.org/index.php/ijms/article/view/295
- Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global,
 regional, and national disability-adjusted life-years (DALYs) for 359 diseases and
 injuries and healthy life expectancy (HALE) for 195 countries and territories,
 1990–2017: a systematic analysis for the Global Burden of Disease Study
 2017. Lancet [Internet]. 2018 Nov 10;392(10159):1859–922. Available from:
 https://doi.org/10.1016/S0140-6736(18)32335-3
- Makoni M. New threats to visceral leishmaniasis control. The Lancet Microbe
 [Internet]. 2021 Nov 1;2(11):e574. Available from: https://doi.org/10.1016/S2666 5247(21)00285-8
- 28. Duthie MS, Goto Y, Ghosh P, Mondal D. Impact of sequelae of visceral
 leishmaniasis and their contribution to ongoing transmission of Leishmania
 donovani. Pathog Dis. 2019 Aug;77(6).
- Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis.
 2010 May;2(2):151–8.
- 30. Meheus F, Abuzaid AA, Baltussen R, Younis BM, Balasegaram M, Khalil EAG, et
 al. The economic burden of visceral leishmaniasis in Sudan: an assessment of
 provider and household costs. Am J Trop Med Hyg. 2013 Dec;89(6):1146–53.
- 394 31. Olobo-Okao J, Sagaki P. Leishmaniasis in Uganda: historical account and a
 395 review of the literature. Pan Afr Med J. 2014;18:16.

396